Red Light Therapy for Alzheimer's Disease: Scientific Evidence

Scores measuring how independently patients managed daily tasks, as rated by their caregivers, rose by 4.33 points in the treatment group compared with a drop of 0.71 points in the control group, in a 2024 human observational study of photobiomodulation (PBM) for Alzheimer's disease and mild cognitive impairment. The study enrolled 13 participants with Alzheimer's disease and mild cognitive impairment, assigning 6 to daily at-home PBM treatment using an 810 nm LED device for 20 minutes each session and 7 to sham treatment, over 12 weeks. Researchers also reported that anxiety and depression scores decreased similarly in both groups, with no significant difference between them, leading the authors to describe PBM as showing promise but requiring further study in larger samples. Based on their observations in this small group, the authors described PBM as a potentially safe approach.

Across 755 participants pooled from multiple clinical trials, a 2023 review synthesized what researchers have learned about illuminating the aging brain to help with Alzheimer's disease, pairing photobiomodulation (PBM) with new drug delivery approaches. The review pooled data using transcranial PBM applied to areas including the forehead, prefrontal cortex, skull, eyes, nose, and midbrain, with wavelengths ranging from 532 to 1080 nm, irradiance levels from 4.2 to 257.4 milliwatts per square centimeter, and doses from 7 to 123.5 joules per square centimeter, with session lengths varying from about 4 to 30 minutes across the studies reviewed. PBM was associated with positive outcomes across the studies examined and may offer a complementary approach for Alzheimer's disease, though protocols varied widely between trials, and further research is needed to standardize treatment. The review also noted that transcranial PBM has a favorable safety profile and can be self-administered at home.

According to a human review published in 2023, researchers evaluated photobiomodulation (PBM) for its potential to reduce amyloid beta toxicity in Alzheimer's disease. The review covered PBM applied to areas including the memory center of the brain, the front, side, and back parts of the brain, the back of the eye, inside the nose, and the skin, using wavelengths ranging from 610 to 1080 nm, with session lengths of 20 to 40 minutes. The authors reported that red and near-infrared light may help break down amyloid beta protein clumps and reduce their toxic effects on brain cells, though the review focused mainly on underlying mechanisms rather than direct patient outcomes.

A 2022 review examined photobiomodulation (PBM) alongside magnetic brain stimulation, mild electrical brain stimulation, and exercise therapy as non-invasive approaches for Alzheimer's disease. The review described PBM protocols applied to areas including the front and side of the head, the base of the skull, the wrist, the nose, the abdomen, the forehead, and the eyes, using wavelengths from 632.8 to 1070 nm and light intensity levels of 20 to 750 milliwatts per square centimeter, with sessions of 90 seconds, 5 times per week, over 84 days. Although treatment settings have not yet been standardized, the authors reported that animal studies showed reduced levels of harmful brain proteins with PBM, and human trials showed improved memory and thinking along with reduced anxiety.

Whether men and women with mild to moderate dementia and Alzheimer's disease respond differently to active near-infrared photobiomodulation (PBM) therapy compared with sham treatment was examined in a 2021 observational trial. The trial enrolled 60 patient and caregiver pairs, ages 50 to 85 with baseline scores of 15 to 24 on a standard memory and thinking test, randomly assigned at a 2 to 1 ratio to active or sham treatment applied to the head and eyes at wavelengths of 1060 to 1080 nanometers, with a light intensity of 23.1 milliwatts per square centimeter, for 6 minute sessions twice daily over 8 weeks. Although memory and thinking test score gains were smaller in the sham group, about 6.5 percent in women and 5.9 percent in men, active treatment produced larger improvements of about 20.2 percent in women and 19.3 percent in men, and researchers noted no meaningful difference between the sexes in either group. The authors also noted that transcranial near-infrared stimulation has previously been described as safe.

10 healthy adults took part in a 2021 observational pilot study testing transcranial photobiomodulation (PBM) as a potential therapeutic target in Alzheimer's disease. The study tested continuous, pulsed, and sham PBM in the same six women and four men, with a mean age of 28.6 years, applying near-infrared light at 830 nm to the forehead at an irradiance of 54.8 milliwatts per square centimeter, for 20 minutes per session, 3 times per week, over 21 days. Continuous PBM significantly increased gamma and beta brain wave activity in the frontal central scalp regions, suggesting a dose-dependent effect, while brain blood flow did not differ from sham.

A human randomized controlled trial published in 2021 evaluated low-level laser therapy (LLLT) for cognitive function and quality of life in elderly patients with Alzheimer's disease and anemia. The placebo-controlled trial enrolled 60 elderly patients with anemia and mild cognitive dysfunction, randomly assigned to an active LLLT group or a placebo LLLT group, with both groups also completing moderate-intensity aerobic exercise, using 650 nm light applied to the nose and wrist for 30 minutes per session, 6 times per week, over 84 days. Researchers found that both groups showed improvements in hemoglobin levels, cognitive scores, quality of life, and balance measures, and reported that combining LLLT with aerobic exercise may be more effective for cognitive function and quality of life than exercise with a placebo laser alone.

A 59-year-old man with mild Alzheimer's disease and type 2 diabetes took part in a 2020 observational case study combining a low-sugar, high-fat eating plan with light therapy delivered through the skull, called photobiomodulation (PBM). The patient, who carried one copy of the ApoE4 gene variant and had an 11-year history of insulin-dependent type 2 diabetes, received PBM at 810 nm, delivered 3 times per week for 20 minutes per session over 10 weeks, alongside the eating plan. The patient's score on a standard memory and thinking test rose from 20 to 26, and a word recall test score improved from 19 to 33 after the combined treatment. The findings come from a single case and cannot establish whether the light therapy or the diet change drove the improvement.

Brain blood flow and connectivity changes were measured alongside memory and thinking scores in a 2019 randomized controlled trial testing home-based photobiomodulation (PBM) therapy against usual care for dementia. The trial randomly assigned 4 participants to usual care and 4 to home-based light therapy applied to the scalp and inside the nose, using red and near-infrared light at 810 nm with light intensity levels of 25 to 100 milliwatts per square centimeter for 20 minutes per session, 3 times per week, over 84 days. Researchers reported that memory and thinking scores improved in the light therapy group while they declined in the usual care group over 12 weeks, a difference they described as statistically significant, though they cautioned that the findings come from a very small sample and require replication in larger trials.

A patient's score on a standard memory and thinking test rose from 18 to 24 after multi-modality photobiomodulation (PBM) therapy in a 2019 human observational case report. The patient received twice daily PBM sessions combining a light helmet worn on the head, a light device placed in the nose, and a light pad on the lower back, using red and near-infrared wavelengths of 635, 658, and 810 nm at light intensity levels of 1.06 to 11.3 milliwatts per square centimeter, for 25 minutes per session over 28 days. The report also described improvement in a working memory survey score from 53 to 10, a better sense of smell, and better quality of life and caregiver stress measures, though the findings are based on a single patient and warrant cautious interpretation. The study also reported no side effects from the treatment.

5 patients with mild to moderately severe dementia took part in a 2017 observational case series testing near-infrared photobiomodulation (PBM) therapy. Participants had starting scores of 10 to 24 on a standard memory and thinking test and received 810 nm near-infrared light delivered through the skull and nose, aimed at several brain areas linked to memory and thinking, at light intensity levels of 14.2 to 41 milliwatts per square centimeter for 20 to 25 minutes, 1 to 7 times per week, over 84 days. Scores on memory and thinking tests improved after 12 weeks of treatment, and researchers noted this came with better sleep, fewer angry outbursts, and less anxiety and wandering, though they cautioned that scores fell again during a 4-week period after treatment stopped. The study also reported no side effects from the treatment.

A human review published in 2016 evaluated photobiomodulation (PBM) as a possible strategy to help prevent Alzheimer's dementia by improving cerebral blood flow. The review described PBM applied to the forehead, scalp, and brain cortex using wavelengths between 780 and 1400 nm, presented as one of several experimental approaches alongside drug-based strategies. The author suggested PBM may help support brain energy production and slow cognitive decline linked to Alzheimer's dementia, though this was presented as a cautious conclusion drawn from a broader literature review rather than a single clinical trial.

Alzheimer's patients at different disease stages may need different light therapy approaches, according to a 2025 review of the brain's fluid clearance system. The review covered light therapy applied to deep brain regions, the outer layer of the brain, the scalp, and the nasal area, using wavelengths mostly between 630 and 1267 nm, light intensity levels of 20 to 70 milliwatts per square centimeter, and device power of 10 to 15 watts, over therapy durations of 30 to 42 days. Early-stage Alzheimer's disease appeared to respond best to red and near-infrared light, though the authors described the overall evidence as only partially effective, noting that treatment settings still vary widely across studies.

Comparing Alzheimer's disease and Parkinson's disease patients, a 2025 human review evaluated the effects of brain photobiomodulation (bPBM) treatment. The review covered bPBM protocols applied to areas including the head, nose, abdomen, neck, wrist, and eyes, using wavelengths from 630 to 1080 nm, irradiance levels from 6 to 250 milliwatts per square centimeter, and doses from 0.9 to 60 joules per square centimeter, with session lengths of 8 to 20 minutes delivered over 28 to 182 days. The authors reported that bPBM showed particularly promising results for Alzheimer's disease, though they described the overall evidence as only partially effective due to inconsistent study quality and design. The review also reported that bPBM appeared safe across the clinical studies examined.

Researchers in 2025 studied the effects of near-infrared (NIR) light therapy, applied across the entire head, on memory and behavior-related symptoms in patients with Alzheimer's disease. The open-label pilot study enrolled 9 patients who wore a light-emitting device covering the whole head, using red to near-infrared light at 810 nm and 100 milliwatts per square centimeter, for 30 minutes per session, 6 times per week, over 120 days. Researchers reported that scores on a standard memory and thinking test improved by a mean of 3.2 points after 4 months of treatment, though they described the overall results as only partially effective, with assessments continuing through 2 months after treatment ended.

In 2024, a human review examined whether photobiomodulation (PBM) could influence gut-brain interactions relevant to Alzheimer's disease. The review covered PBM applied to the head and abdomen using wavelengths across three ranges, 620 to 780 nm, 780 to 1400 nm, and 1400 to 3000 nm, with sessions of 10 minutes over a therapy duration of 182 days. The authors suggested that PBM may help modulate interactions between gut bacteria and the immune system that are linked to Alzheimer's disease, though they described the evidence as only partially effective and still emerging. The review also described PBM as a safe, non-invasive therapy.

A 2023 systematic human review compared nighttime and daytime photobiomodulation (PBM) treatment for Alzheimer's disease, focusing on the brain's natural waste drainage system. The review covered light therapy applied through the skull and inside the nose using wavelengths from 610 to 1267 nm, doses from 1.2 to 60 joules per square centimeter, and session lengths from 90 seconds to 25 minutes, delivered from 1 to 56 times per week over 28 to 112 days. Although the authors described the overall evidence as only partially effective and still developing, they reported that light therapy applied during sleep may boost the brain's natural cleanup process more effectively than daytime treatment, potentially slowing the buildup of a harmful brain protein. Mild and temporary eyesight-related side effects have been reported in some cases, though the review noted that PBM is generally considered safe.

From tangled proteins to leaky blood vessels, researchers have chased many different culprits behind Alzheimer's disease, and a 2023 review added photobiomodulation (PBM) to the growing list of potential defenses. The review covered transcranial near-infrared light protocols applied to the scalp, skull, and neck arteries, using wavelengths from 600 to 1700 nm, doses from 0.0032 to 60 joules per square centimeter, and sessions of 60 seconds to 6 minutes delivered up to 14 times per week. The authors described PBM as a promising but not yet proven approach for reducing harmful inflammation and improving blood flow in the brain, reporting partially effective results across the studies discussed.

57 percent of participants who received near-infrared (NIR) light treatment showed a meaningful improvement on the Mini-Mental State Examination, compared with 14 percent in the control group, in a 2023 randomized controlled trial for mild to moderate Alzheimer's disease. The trial randomly assigned 20 participants with mild to moderate Alzheimer's disease to receive transcranial NIR light at wavelengths of 800 to 820 nm and 1060 to 1080 nm, or to a control group with no treatment, over a therapy duration of 84 days. Significant improvements in activities of daily living scores were reported for the treatment group compared with the control group. However, the difference on a separate cognitive scale, the ADAS Cog, did not reach statistical significance, leading the authors to describe the therapy as only partially effective. It was also found that NIR light treatment did not increase the rate of adverse events compared with the control group.

According to a human review published in 2015, researchers evaluated near-infrared light therapy (NIr) as a possible strategy to help protect neurons in Alzheimer's disease and Parkinson's disease. The review described NIr applied to the brain, cortex, brainstem, cranium, and dorsum using wavelengths between 600 and 1070 nm and irradiance levels between 1 and 750 milliwatts per square centimeter, drawn mainly from preclinical and laboratory studies. Findings on NIr remain preliminary, but the authors noted the therapy may offer a possible way to protect neurons from damage in both conditions. The review also noted that NIr has been described as safe based on the studies covered.

Pharmacology, near-infrared light therapy, and nutrition were weighed as three possible approaches to supporting how brain cells produce and use energy in a 2014 human review focused on Alzheimer's disease. The review described transcranial low-level light therapy (LLLT) using near-infrared light between 600 and 1100 nm applied to the brain as one of these approaches for helping brain cells work more efficiently. The authors suggested this approach may hold promise for brain energy use and thinking ability, though the evidence was reported as only partially effective for the outcomes discussed.

Researchers tracked memory and thinking test scores before and after 28 days of near-infrared (NIR) light treatment in a 2017 human observational pilot trial for dementia. The trial enrolled 11 adults aged 40 to 85 with scores of 15 to 25 on a standard memory and thinking test, assigning 6 to active NIR treatment and 3 to placebo, with 2 withdrawing, and applied 6-minute sessions to the outer surface of the brain at 1060 to 1080 nm daily for 28 consecutive days. Researchers reported that scores did not differ significantly between the NIR and placebo groups after treatment, though they noted a trend toward improved brain wave activity.